Amplitude-modulated electromagnetic fields for the treatment of cancer [Archive]

Rich66

04-19-2009, 05:04 PM

Process called Intrabuccally-administered amplitude-modulated RFEM

23 page PDF is here:
http://www.jeccr.com/content/pdf/1756-9966-28-51.pdf

<dl class="AbstractPlusReport"><dt class="head">1: J Exp Clin Cancer Res. (http://javascript%3Cb%3E%3C/b%3E:AL_get%28this,%20%27jour%27,%20%27J%20Exp%20C lin%20Cancer%20Res.%27%29;) 2009 Apr 14;28(1):51. [Epub ahead of print] <script language="JavaScript1.2"></script>Links (http://javascript%3Cb%3E%3C/b%3E:PopUpMenu2_Set%28Menu19366446%29;)
</dt><dd class="abstract"> Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach.

Barbault A (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Barbault%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Costa FP (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Costa%20FP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Bottger B (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bottger%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Munden RF (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Munden%20RF%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Bomholt F (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bomholt%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Kuster N (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kuster%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Pasche B (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pasche%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus).
ABSTRACT: PURPOSE: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. PATIENTS AND METHOD: S: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. RESULTS: : We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). CONCLUSION: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Trial registration: clinicaltrials.gov identifier NCT00805337.</dd></dl>

Main contact here:
Boris Pasche
University of Alabama at Birmingham Comprehensive Cancer Center
Phone: 205-934-9591 Fax: 205-996-5975 boris.pasche@ccc.uab.edu

Rich66

04-19-2009, 05:29 PM

An interesting excerpt from the PDF:

The evolution of treatment programs through incremental addition of tumor-specific frequencies is illustrated by
the case of a 51 year old woman with ovarian cancer. This patient was diagnosed with FIGO stage III (G2-G3)
ovarian cancer in October 1997 and had received multiple courses of palliative chemotherapy until 2005. As
seen on Figure 2, the initial treatment consisting of 15 frequencies did not yield any response. Upon reexamination,
11 additional frequencies (total of 26) were added to the treatment program in August 05.
Because of disease progression, treatment with single agent bevacizumab was initiated in November 05.
Interestingly, the CA 125 level had decreased by 200 units between October and November 2005, prior to the
initiation of bevacizumab. Combined treatment with amplitude-modulated electromagnetic fields and
bevacizumab resulted in a decrease in CA 125 level from 2140 to 540 in May 06. Treatment was
supplemented with cyclophosphamide from March to September 07. The patient was hospitalized with
pneumonia and elected to only receive amplitude-modulated electromagnetic fields since September 07. As of
April 1, 2009 the patient has stable disease and is asymptomatic. She has been receiving experimental
treatment without interruption for a total of +50.5 months.